Despite the fact, that GPR35 agonists have not been directly related to pro- or antiproliferative activity towards cancer cells to date, GPR35 signalling via ERK kinase is involved in several processes including proliferation, cell survival and metastasis [93] (Fig. 3b). Here, GPR35 is linked to cancer.